Absorption, Distribution and Excretion
Repeated administration does not cause accumulation. Biological Half-Life Unknown... Plasma half-life, 3-5 days...

Protein Binding
Unknown Interactions Corticotropin and adrenocorticotropic hormones… have been reported to cause serious bleeding when used in combination with oral anticoagulants… This is puzzling because thrombotic events are more common in patients receiving steroid therapy, while oral anticoagulants… are recommended for the prevention of such complications. Oral Anticoagulants High doses of salicylates are often associated with bleeding problems, especially in patients receiving oral anticoagulants. This may be due to direct gastric irritation, platelet inhibition, or the effects of true hypoprothrombinemia. The latter is antagonized by vitamin K. Oral Anticoagulants Antibiotics and other medications that alter the gut microbiota may enhance the anti-vitamin K effects of oral anticoagulants, but this is generally not the case unless there is a vitamin K deficiency in the diet. Oral Anticoagulants Thiazide diuretics and ethacrynic acid may enhance the effects of oral anticoagulants. /Oral Anticoagulants/
For more complete data on interactions of anisinones (21 in total), please visit the HSDB record page.

Therapeutic Uses
Oral anticoagulants can be used for the prevention and treatment of a variety of thromboembolic diseases. /Oral Anticoagulants/
...Indications for anticoagulants...myocardial infarction...rheumatic heart disease...cerebrovascular disease...venous thrombosis and pulmonary embolism, and...disseminated intravascular coagulation. /Oral Anticoagulants/
Oral anticoagulants are used to prevent the progression or recurrence of acute deep vein thrombosis or pulmonary embolism after an initial course of heparin therapy. They are also effective in preventing venous thromboembolism in patients undergoing orthopedic or gynecological surgery, and systemic embolism in patients with acute myocardial infarction, artificial heart valve replacement, or chronic atrial fibrillation. /Oral Anticoagulants/
Anticoagulants are indicated for the prevention and/or treatment of venous (or arterial/not included on US product label/) thrombosis (and its spread) and pulmonary embolism, deep vein thrombosis (DVP), or pulmonary embolism (treatment). Oral anticoagulants are used during and after initial heparin therapy to reduce the risk of thrombus spread, recurrence, or death. /Anticoagulant; included in the US product label/
For more complete data on the therapeutic uses of phenylindanedion (11 in total), please visit the HSDB record page.

---

Drug Warning
Serious and even fatal toxic reactions have been reported in patients receiving phenylindanedion (currently discontinued in the US). Patients receiving phenylindanedion should consider the possibility of such reactions. Adverse reactions reported with benzoindone (no longer sold in the US) include skin reactions such as urticaria and rashes (usually erythema and macules), which sometimes develop into exfoliative dermatitis; nephrotic reactions, including anuria and proteinuria with significant edema and tubular necrosis; hepatotoxicity, manifested as hepatitis and jaundice; and hematologic reactions such as eosinophilia, agranulocytosis or leukopenia (caused by maturation arrest or granulocyte dysplasia), leukocytosis, anemia, thrombocytopenia, atypical mononucleosis, presence of leukocyte agglutinins, agranulocytosis, aplastic anemia, and erythrocyte aplasia. In addition, patients taking this drug have reported hemorrhagic infarction and skin necrosis, alopecia, steatorrhea, sore throat and mouth, accommodation paralysis and blurred vision, diarrhea, nausea, fever, fatigue, and headache. Patients with alkaline urine may experience reddish-orange urine during treatment with anisole; this possibility should be explained to them.
The only consistently reported non-hemorrhagic adverse reaction to anisole is dermatitis. However, agranulocytosis and hepatitis have also been reported with this drug.
Conversely, anisoledione (plasma half-life 3-5 days)...has such a long duration of action that...bleeding could be dangerous...
For more complete data on anisoledione (30 total), please visit the HSDB records page.

---

Pharmacodynamics
Anisoledione is a synthetic anticoagulant and an indanedione derivative. Because anisoledione is a potent drug with serious potential side effects, it is only prescribed if you cannot take coumarin anticoagulants (such as warfarin). Anticoagulants reduce the blood's ability to clot, thus helping to prevent harmful blood clots from forming in blood vessels. These drugs are sometimes called blood thinners, although they do not actually thin the blood. They do not dissolve clots that have already formed, but they prevent clots from growing larger, thus avoiding more serious problems.

C16H12O3

252.26468

252.079

117-37-3

2197

Pale yellow crystals from acetic acid or ethanol
FINE WHITE TO CREAM-WHITE CRYSTALLINE POWDER

1.263g/cm3

443.9ºC at 760mmHg

155-156
156-157 °C
156.5 °C

199.8ºC

4.45E-08mmHg at 25°C

1.616

2.858

0

3

2

19

344

0

O=C1C(C2=CC=C(OC)C=C2)C(C3=C1C=CC=C3)=O

XRCFXMGQEVUZFC-UHFFFAOYSA-N

InChI=1S/C16H12O3/c1-19-11-8-6-10(7-9-11)14-15(17)12-4-2-3-5-13(12)16(14)18/h2-9,14H,1H3

2-(4-methoxyphenyl)indene-1,3-dione

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO : ≥ 50 mg/mL (~198.21 mM)

Solubility in Formulation 1: ≥ 2.5 mg/mL (9.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

Solubility in Formulation 2: ≥ 2.5 mg/mL (9.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

---

 (Please use freshly prepared in vivo formulations for optimal results.)